hematopoietic stem cell transplantation: high risk diffuse large cell lymphoma:
DESCRIPTION
Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma:. Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford University Medical Center. - PowerPoint PPT PresentationTRANSCRIPT
Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma:
Ginna G. Laport, MDAssociate Professor of Medicine
Division of Blood & Marrow TransplantationStanford University Medical Center
Diffuse Large B-Cell Lymphoma:Stem Cell Transplantation for High Risk
Patients
• Identifying “High Risk” Patients
• Autologous HSCT in High Risk Patients• Phase II Trials• Phase III Trials
• Allogeneic HCT
Tran
spla
nts
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
'68 '70 '72 '74 '76 '78 '80 '82 '84 '86 '88 '90 '92 '94 '96 '98 '00 '02 '04 '06 '08 '10 '12
AutologousAllogeneic
Transplant Activity Worldwide1968-2012
Indications for Hematopoietic Stem Cell Transplants in the U.S.
Num
ber o
f Tra
nspl
ants
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
5,500
MultipleMyeloma
NHL AML HD ALL MDS/MPD AplasticAnemia
CML OtherLeuk
Non-Malig
Disease
OtherCancer
Allogeneic (Total N=7,012)Autologous (Total N=9,778)
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Most common NHL: 31%– Peak incidence in 6th decade
Large cells with loss of follicular architecture of node– 30% to 40% present with rapidly enlarging, symptomatic mass
with B symptoms
Frontline chemotherapy (anthracycline-based + RTX)– CR 50-60%– Long term remission -> 30-35%
Diffuse Large B-Cell Lymphoma
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
5Yrs
P < .001
1.00.90.80.70.60.50.40.30.20.1
00 1 2 3 4
Sehn LH, et al. Blood. 2007;109:1857
Legend Revised IPI Risk Group
IPI Factors, n
Very good 0Good 1, 2Poor 3, 4, 5
• Age >60• Perf
Status• Stage 3-4• LDH• Extranodal
Overall Survival According to Revised International Prognostic Index
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Yrs
OS
Diffuse Large B-Cell Lymphoma
DLBCL Subgroup 5-Yr OS, %Primary Mediastinal 64Germinal Center B cell like (GCB) 59
Activated B cell (ABC) 30
1.0
0.8
0.6
0.4
0.2
00 2 4 6 8 10
Rosenwald A, et al. J Exp Med. 2003;198:851-862.
Survival by Gene Expression Profiling: DLBCL
Prognosis By Interim PET Scanning- Mixed results seen in 4 studies- 2 studies confirm predictive value, 2 studies did not
Safar et al, J Clin Oncol 2012;30:184
0
20
40
60
80
100
0 20 40 60 80 100Time (months)
PET positive (n=12)
P=0.02
PET negative (n=73)
Progression Free Survivaln= 98
0
0.2
0.4
0.6
0.8
1.0
0 1 3 5 6 7Time (years)
PET Positive
P=0.146
PET Negative
2 4
Moskowicz et al. J Clin Oncol 2010;11: 1896
Progression Free Survivaln= 112
High Risk DiffuseLarge Cell Lymphoma
AutologousHSCT in First CR/PR
High Risk Diffuse Large B Cell NHL:Frontline Autologous HCT
Phase II Trials containing rituximab
Group n aaIPI >2 Therapy CR
RatePFS/EFS OS Follow
upTarella2007 112 100 Mod R-HDS 80 73 76 4 yrs
Vitolo2009 97 100 R-mega CEOP x
BEAM/HCT 82 73 80 4 yrs
Dilhudy2010 42 100 R CEEP BEAM
HCT 55 55 74 5 yrs
Fitoussi2011 209 100 R-ACVBP +
BEAM/HCT 60 76 78 4 yrs
Cochrane Database Sys Rev 2008;CD004024
Meta-analysis:Autologous HSCT as Front Line Therapy
N = 2228No survival advantage for autologous HSCT in CR1
Haematologica 2003;88:1304
N = 3079Overall survival advantage for autologous HSCT in CR1
compared to chemotherapy
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Pts with ≥ PR after CHOP
± RTX x 5 (N = 253)
CHOP ± Rituximab x 1 + Autologou HSCT*
(n = 125)
CHOP ± Rituximab x 3 (n = 128)
Stiff PJ, et al. ASCO 2011. Abst 8001.
R-CHOP x 8 vs R-CHOP x 6 Cycles + Autologous HSCT
(SWOG S9704)
Eligibility: Bulky stage 2-4 Hi-int/High IPI
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Stiff PJ, et al. ASCO 2011. Abstr 8001.
Outcome, % CHOP ± R + AutoSCT(n = 125)
CHOP ± R(n = 128)
P Value
2-yr PFS (all) 69% 56% .005 High-interm IPI 60% 63 % High IPI 75% 47 % .022-yr OS (all) 74% 71% .16 High-inter IPI pts 70% 75% High IPI pts 82% 64% .01
Autologous HSCT prolonged PFS high-intermediate high-IPI
Autologous HSCT prolonged OS high-IPI
ASCT After CHOP ± Rtx Improves PFS in Advanced High-Risk Diffuse NHL
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Newly diagnosedDLBCL,aaIPI > 2n = 399
RANDOMIZE
R-CHOPx 3
R-megaCHOP
SD, PDoff study
PR, CR
Ann Oncol 2011; 22 suppl 4: abstr 72.
RANDOMIZE
BEAM AutoHCT
Observation only
Italian Lymphoma Foundation2 x 2 Randomized Trial with Autologous HSCT in
High Risk Patients
Italian Lymphoma Foundation2 x 2 Randomized Trial with Autologous HCT in High Risk Patients
(median followup = 23 mos)
PFS OSNo BMT 59 83
BMT 72 83
P value .008 NS
- Risk of relapse was 53% lower in BMT patients- No overall survival difference between two arms`
0 6 12 18 24 30 36 42 48
Months
0.00
0.25
0.50
0.75
1.00HDT
No-HDT
Progression Free Survival
P=.008
High Risk DiffuseLarge Cell Lymphoma
Is there a role for allogeneic HSCT??
Years0 2 61 3 4 5
Survival after Allogeneic HCT for Diffuse Large B-Cell Lymphoma, 2000-2009
- By Disease Status -
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sensitive (N=383)
Resistant (N=124)
Reduced Intensity Allogeneic HSCT (after autologous HSCT relapse)
n Ablat/RIC OS PFS NRM F/U
EBMT 101 37%; 64% 53% 41% 28% 3 yrs
Italian 165 30%; 70% 39% 32% 28% 2 yrs
• Factors affecting outcomes• Dz status at time of allogeneic HCT• Time to relapse after autologous HCT (< 12 m vs >
12 m)• Did not affect outcome
• Prep regimen
Rigacci et al , Ann Heme 2012;91:931van Kampen et al. JCO 2011;29:1342
• Need better tools to identify high risk patients
• Current studies suggest that high-IPI subtype may benefit from autologous HCT early as front line therapy
• More studies needed to further define role of autologous HSCT as front line therapy– Need study that includes only ABC-subtype
• Role of allogeneic HSCT in high risk population?
Hematopoietic SCT for High Risk DLBCL
Stanford University
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Relapsed/ refractoryDLBCLn = 396
RANDOMIZE
R-ICEx 3
R-DHAPx 3
AutoSCT
SD, PDoff study
PR, CR
J Clin Oncol 2010; 28:4184–4190.
Which salvage regimen is the best?
RANDOMIZE
Rituximab q2mos x 6
Observation only
Role of maintenance rituximab
CORAL Trial:Collaborative Trial in Relapsed Aggressive Lymphoma
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Overall Survival Event Free Survival
P = .49
Mos0 12 36 60
1.0
0.8
0.6
0.4
0.2
0P = .27
Mos0 12 24 36
0.8
0.6
0.4
0.2
0
1.0R-ICER-DHAP
60 724824 48 72
CORAL TrialSurvival according to Salvage Regimen
GCB vs ABC 3 yr PFS: 70% vs 28%R-DHAP vs R-ICE in GCB pts: 3 yr PFS: 100% vs 27%
CORAL Trial: EFS by relapse time after initial therapy
Relapse > 12 mos from dx Relapse < 12 mos from dx
Relapse < 12 mos from dx predicted for poor outcome after autologous HCT
JCO 2012, In press
EFS
RTX
Obsp=.74
PFS
Female
Male
p=.04
Female pts benefited from RTX maintenance
CORAL: Factors affecting survival in relapsed DLCL patients
EFS OS
Prior rituximab .0007 .01
Relapse < 12 mos <.0001 <.0001
sIPI <.0004 <.0001
R-DHAP vs R-ICE 0.3 0.7(Except for GCB pts)
p
clinicaloptions.com/oncologyEvolving Options and Challenges in Mantle Cell Lymphoma
Philip T, et al. N Engl J Med. 1995;333:1540
P = .0010
20
40
60
80
100
EFS
(%)
0 15 30 45 60 9075Mos After Randomization
P = .0380
20
40
60
80
100
OS
(%)
0 15 30 45 60 9075Mos After Randomization
TransplantationConventional treatment
PARMA Study: BMT vs Salvage Chemotx for Relapsed DLBCL
Event Free Survival Overall Survival